Bone Biologics Corporation (BBLG) Stock Score, Valuation & Financial Research

Bone Biologics Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BBLG

Bone Biologics Corporation does not currently have a complete Wall Street Score. The stored market price is USD 0.50. These figures are a research snapshot, not a buy or sell recommendation.

What Bone Biologics Corporation does

Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Bone Biologics is a clinical-stage medical device company that does not currently generate revenue from product sales. Its business model is focused on the development and commercialization of its proprietary NELL-1 protein technology for bone regeneration in spinal fusion procedures, relying on capital raises to fund research, development, and clinical trials.

Products and services

  • The company's primary product candidate is NB1, a bone graft device consisting of recombinant human NELL-1 protein combined with demineralized bone matrix (DBM) designed for spinal fusion surgery.

Brands and product families

  • NB1 — The company's lead bone graft device candidate currently in clinical trials. Source

Customer types

Hospitals and surgical centers performing spinal fusion procedures.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its clinical trial materials and product candidates. Source

Business relationships and partnerships

  • UCLA Technology Development Group — The company holds an exclusive worldwide license for the NELL-1 technology platform through a technology transfer agreement with UCLA. Source

Competitors and product-market comparisons

  • Medtronic — Competes in the spinal fusion and bone graft market with products such as Infuse Bone Graft. Source
  • Stryker Corporation — Competes in the orthopedic and spinal implant market. Source
  • Zimmer Biomet — Competes in the musculoskeletal healthcare and spinal surgery market. Source

Business strengths to evaluate

  • Proprietary NELL-1 technology platform with exclusive worldwide licensing rights Source
  • Targeted application in the large spinal fusion orthopedic market Source

Business risks and research considerations

  • Clinical-stage status with no history of product revenue and significant operating losses Source
  • Dependence on successful clinical trial outcomes and regulatory approval from the FDA Source
  • Reliance on third-party manufacturers and suppliers for product development Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BBLG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.50
Market capitalization:
898.49K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -2.89M
Free cash flow:
USD -2.69M
Cash:
USD 4.03M
Total debt:
USD 0.00
EPS:
USD -1.86

What stands out

  • Free cash flow is USD -2.69M, negative for the stored period.
  • The balance sheet shows USD 4.03M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BBLG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BBLG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BBLG likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BBLG to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BBLG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research BBLG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.